Long Non-Coding H19 in Lymphocytes: Prognostic Value in Acute Ischemic Stroke Patients

Area of Science:

• Biomedical research
• Molecular biology
• Neurology

Background:

• Acute ischemic stroke (AIS) poses significant challenges to patient health and quality of life.
• Current prognostic prediction methods for AIS are insufficient.
• Identifying reliable biomarkers is crucial for improving AIS patient outcomes.

Purpose of the Study:

• To evaluate the prognostic value of long non-coding RNA (lncRNA) H19 in lymphocytes of AIS patients.
• To develop a prognostic prediction model for AIS incorporating lncRNA H19.
• To explore lncRNA H19 as a potential therapeutic target for AIS.

Main Methods:

• Quantitative real-time polymerase chain reaction (qRT-PCR) to measure lncRNA H19 levels in lymphocytes.
• Spearman correlation analysis to assess the relationship between lncRNA H19 and clinical outcomes (mRS score, blood cell counts).
• Logistic regression analysis to identify independent predictors of poor prognosis.
• Development of a nomogram prediction model.

Main Results:

• lncRNA H19 showed a positive correlation with 3-month modified Rankin scale (mRS) scores in AIS patients.
• lncRNA H19 levels were negatively correlated with white blood cells, lymphocytes, and neutrophils counts.
• lncRNA H19 was identified as an independent predictor of poor prognosis in AIS (OR = 3.062, p < 0.001).
• A nomogram model incorporating lncRNA H19 demonstrated effective prediction of AIS outcomes.

Conclusions:

• lncRNA H19 in lymphocytes is a valuable prognostic indicator for AIS.
• lncRNA H19 may serve as a potential pharmacological target for AIS treatment.
• This research offers novel insights for prognostic evaluation and targeted therapies in AIS.